Home > Analyses > Healthcare > STERIS plc
STERIS plc plays a critical role in safeguarding health by delivering advanced infection prevention and sterilization solutions that hospitals and pharmaceutical companies rely on daily. As a prominent player in the medical devices industry, STERIS stands out with its comprehensive portfolio spanning healthcare, life sciences, and dental sectors, backed by a reputation for innovation and quality. In an evolving healthcare landscape, I explore whether STERIS’s solid fundamentals continue to support its premium valuation and growth prospects.
Table of contents
Business Model & Company Overview
STERIS plc, founded in 1985 and headquartered in Dublin, Ireland, stands as a leading force in the medical devices industry. Its comprehensive ecosystem spans infection prevention, sterilization technologies, life sciences, and dental products, creating a cohesive suite of solutions that serve hospitals, healthcare providers, and pharmaceutical manufacturers globally. With 18,000 employees, STERIS integrates capital equipment, consumables, and procedural services to ensure sterile environments and operational efficiency in clinical settings.
The company’s revenue engine balances hardware sales—such as sterilizers and surgical equipment—with recurring service contracts including maintenance, repair, and process consulting. STERIS operates a strategic global footprint across the Americas, Europe, and Asia, supported by around 50 sterilization facilities to meet diverse market demands. Its economic moat is anchored in its specialized service network and product integration, shaping the future of infection prevention and sterile processing worldwide.
Financial Performance & Fundamental Metrics
In this section, I analyze STERIS plc’s income statement, key financial ratios, and dividend payout policy to assess its overall financial health and investor value.
Income Statement
The following table presents STERIS plc’s key income statement figures for the fiscal years 2021 through 2025, reported in USD.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | 3.11B | 4.22B | 4.54B | 5.14B | 5.46B |
| Cost of Revenue | 1.76B | 2.34B | 2.56B | 2.92B | 3.06B |
| Operating Expenses | 795M | 1.41B | 1.19B | 1.38B | 1.54B |
| Gross Profit | 1.34B | 1.88B | 1.98B | 2.22B | 2.40B |
| EBITDA | 774M | 1.01B | 1.34B | 1.41B | 1.36B |
| EBIT | 555M | 456M | 791M | 847M | 882M |
| Interest Expense | 37.2M | 89.5M | 110.8M | 144.4M | 86.3M |
| Net Income | 397M | 244M | 107M | 378M | 615M |
| EPS | 4.66 | 2.50 | 1.07 | 3.83 | 6.24 |
| Filing Date | 2021-05-28 | 2022-05-31 | 2023-05-10 | 2024-05-29 | 2025-05-29 |
Income Statement Evolution
STERIS plc’s revenue increased steadily from 3.11B in 2021 to 5.46B in 2025, marking a favorable 75.69% growth over five years, though the latest one-year growth was neutral at 6.24%. Net income rose from 397M in 2021 to 615M in 2025, with a strong one-year net margin growth of 52.95%, despite a slight overall net margin decline of 11.97%. Margins remain generally favorable, with gross margin at 44.01% and EBIT margin at 16.16%.
Is the Income Statement Favorable?
In 2025, STERIS reported a net income of 615M on 5.46B revenue, reflecting an 11.26% net margin, considered favorable. EPS jumped 62.73% year-over-year to 6.24, supporting strong profitability. Interest expense remains low at 1.58% of revenue. Operating expenses grew by 6.24%, slightly outpacing revenue growth, signaling a need to monitor cost control. Overall, the income statement fundamentals appear favorable for 2025.
Financial Ratios
The following table summarizes key financial ratios for STERIS plc (STE) over the fiscal years 2021 to 2025, providing insights into profitability, liquidity, leverage, and market valuation:
| Ratios | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Margin | 13% | 6% | 2% | 7% | 11% |
| ROE | 10% | 4% | 2% | 6% | 9% |
| ROIC | 7% | 3% | 6% | 6% | 7% |
| P/E | 41 | 97 | 178 | 58 | 36 |
| P/B | 4.18 | 3.61 | 3.14 | 3.46 | 3.38 |
| Current Ratio | 2.10 | 2.04 | 2.33 | 3.08 | 1.96 |
| Quick Ratio | 1.55 | 1.41 | 1.63 | 2.36 | 1.39 |
| D/E | 0.46 | 0.50 | 0.53 | 0.54 | 0.33 |
| Debt-to-Assets | 27% | 29% | 30% | 31% | 22% |
| Interest Coverage | 15 | 5.3 | 7.1 | 5.8 | 10 |
| Asset Turnover | 0.47 | 0.37 | 0.42 | 0.46 | 0.54 |
| Fixed Asset Turnover | 2.24 | 2.43 | 2.52 | 2.65 | 2.58 |
| Dividend Yield | 0.8% | 0.7% | 1.0% | 0.9% | 1.0% |
Evolution of Financial Ratios
From 2021 to 2025, STERIS plc’s Return on Equity (ROE) showed a declining trend, dropping from 10.24% in 2021 to 9.31% in 2025, indicating a slowdown in profitability growth. The Current Ratio improved overall, reaching 1.96 in 2025 after some fluctuations, reflecting stable liquidity. The Debt-to-Equity Ratio decreased from 0.46 in 2021 to 0.33 in 2025, signaling a reduction in financial leverage and enhanced balance sheet strength.
Are the Financial Ratios Favorable?
In 2025, profitability ratios were mixed: net margin was favorable at 11.26%, while ROE and market valuation ratios like Price-to-Earnings (36.35) and Price-to-Book (3.38) were unfavorable. Liquidity ratios, including the Current Ratio (1.96) and Quick Ratio (1.39), were favorable, supporting short-term financial health. Leverage ratios such as Debt-to-Equity (0.33) and Debt-to-Assets (21.71%) were favorable, complemented by a strong interest coverage ratio of 10.23. Efficiency ratios were neutral, with asset turnover at 0.54. Overall, the financial ratios present a slightly favorable profile.
Shareholder Return Policy
STERIS plc maintains a consistent dividend policy with a payout ratio around 36%, a stable dividend per share increasing from $1.57 in 2021 to $2.23 in 2025, and a dividend yield near 0.98%. Share buybacks are not explicitly reported, but dividend payments are well covered by free cash flow, supporting financial stability.
The company’s approach to shareholder returns balances dividend distributions with prudent capital management, avoiding overly aggressive payouts or repurchases. This policy appears aligned with sustaining long-term shareholder value, given steady profitability and solid cash flow coverage ratios over recent years.
Score analysis
The following radar chart presents a comprehensive view of the company’s key financial scores:
STERIS plc shows a favorable discounted cash flow score of 4 and a strong return on assets score of 4, with moderate scores for return on equity, debt to equity, price to earnings, and price to book ratios, all indicating balanced financial metrics.
Analysis of the company’s bankruptcy risk
The Altman Z-Score of STERIS plc positions the company well within the safe zone, indicating low bankruptcy risk and financial stability:
Is the company in good financial health?
This Piotroski diagram highlights the company’s financial strength based on nine key criteria:
STERIS plc’s Piotroski Score of 8 reflects a very strong financial position, suggesting robust profitability, liquidity, and operational efficiency across recent periods.
Competitive Landscape & Sector Positioning
This sector analysis will examine STERIS plc’s strategic positioning, revenue breakdown, key products, and main competitors. I will assess whether STERIS holds a competitive advantage over its industry peers in the healthcare medical devices sector.
Strategic Positioning
STERIS plc maintains a diversified product portfolio across healthcare, applied sterilization, life sciences, and dental segments, with roughly balanced revenue from products (~2.87B) and services (~2.59B) in FY 2025. Geographically, it is concentrated in the United States (4.01B), with significant exposure to other foreign markets (1.34B) and Ireland (107M), reflecting a broad international presence.
Revenue by Segment
This pie chart illustrates the revenue distribution between Product and Service segments for STERIS plc during the fiscal year 2025.
In 2025, STERIS’s revenue shows a balanced contribution from Product at 2.87B USD and Service at 2.59B USD. Over recent years, both segments have steadily grown, with Product revenue increasing from 1.30B USD in 2019 to 2.87B USD in 2025, and Service revenue rising from 1.49B USD to 2.59B USD. The growth indicates a well-diversified business with no excessive reliance on a single segment, reflecting steady expansion and risk-managed revenue streams.
Key Products & Brands
The table below outlines STERIS plc’s main products and brands, highlighting their descriptions:
| Product | Description |
|---|---|
| Healthcare Segment Products | Cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, GI procedure accessories, washers, sterilizers, surgical tables, lights, and connectivity solutions for operating rooms. |
| Healthcare Services | Capital equipment installation, maintenance, upgradation, repair, troubleshooting, preventive maintenance, instrument and endoscope repair, consulting, and outsourced sterile processing services. |
| Applied Sterilization Technologies | Contract sterilization and testing services for medical device and pharmaceutical manufacturers via ~50 facilities worldwide. |
| Life Sciences Products | Consumables including formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. |
| Life Sciences Services | Equipment installation, maintenance, upgradation, repair, troubleshooting, and preventive maintenance programs. |
| Dental Segment Products | Hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suites. |
STERIS plc’s portfolio spans a wide range of infection prevention and procedural products along with comprehensive equipment services, serving healthcare providers and pharmaceutical clients globally.
Main Competitors
The Healthcare sector in Medical – Devices includes 10 main competitors, with the table below listing the top 10 leaders by market capitalization:
| Competitor | Market Cap. |
|---|---|
| Abbott Laboratories | 216B |
| Boston Scientific Corporation | 140B |
| Stryker Corporation | 133B |
| Medtronic plc | 123B |
| Edwards Lifesciences Corporation | 50B |
| DexCom, Inc. | 26B |
| STERIS plc | 24.6B |
| Insulet Corporation | 19.9B |
| Zimmer Biomet Holdings, Inc. | 17.8B |
| Align Technology, Inc. | 11.2B |
STERIS plc ranks 7th among these competitors, with a market capitalization at 11.82% of the sector leader, Abbott Laboratories. The company’s market cap is below both the average market cap of the top 10 competitors (76.3B) and the sector median (38.1B). It maintains a narrow 1.84% gap above its closest competitor, DexCom, highlighting a competitive position within the lower half of the top 10.
Comparisons with competitors
Check out how we compare the company to its competitors:
Does STE have a competitive advantage?
STERIS plc currently shows a slightly unfavorable competitive advantage as its return on invested capital (ROIC) is below its weighted average cost of capital (WACC), indicating value is being shed despite growing profitability. The company maintains favorable income statement metrics, including a 44.01% gross margin and 11.26% net margin, supporting operational efficiency.
Looking ahead, STERIS’s broad product portfolio across Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental segments positions it well to capitalize on expanding markets and innovation opportunities. Continued growth in revenue, especially in the United States and other foreign locations, alongside new equipment and service offerings, may support future competitive positioning.
SWOT Analysis
This SWOT analysis highlights STERIS plc’s key strategic factors to inform investment decisions.
Strengths
- strong global presence with diversified segments
- favorable gross margin of 44%
- solid net margin growth of 53% in 1 year
Weaknesses
- relatively high P/E ratio at 36.35
- moderate return on equity at 9.31%
- unfavorable net margin growth over 5 years (-12%)
Opportunities
- expanding healthcare infrastructure worldwide
- growth in infection prevention demand
- rising Life Sciences and contract sterilization markets
Threats
- intense competition in medical devices sector
- regulatory changes in healthcare
- economic fluctuations impacting capital equipment investments
Overall, STERIS shows robust profitability and growth in key areas but faces valuation and efficiency challenges. Strategic focus should leverage its global reach and innovation to capture market opportunities while managing operational efficiency and competitive risks.
Stock Price Action Analysis
The following weekly chart displays STERIS plc’s stock price movement over the last 100 weeks, highlighting key fluctuations and price levels:
Trend Analysis
Over the past 12 months, STERIS plc’s stock price increased by 11.49%, indicating a bullish trend. The price ranged between 199.51 and 268.65, with volatility reflected in a 15.58 standard deviation. Recently, from November 2025 to January 2026, the trend slightly decelerated with a -1.61% change, signaling a neutral short-term slope of -0.36.
Volume Analysis
In the last three months, trading volume for STERIS plc has been increasing, with buyers dominating 60.07% of activity. Buyer volume totaled 20.8M shares versus 13.8M seller shares, suggesting positive investor sentiment and heightened market participation during this period.
Target Prices
Analysts present a confident target consensus for STERIS plc, indicating positive growth expectations.
| Target High | Target Low | Consensus |
|---|---|---|
| 265 | 245 | 256.67 |
The target prices suggest a bullish outlook, with most analysts expecting the stock to trade between 245 and 265, averaging around 257.
Don’t Let Luck Decide Your Entry Point
Optimize your entry points with our advanced ProRealTime indicators. You’ll get efficient buy signals with precise price targets for maximum performance. Start outperforming now!
Analyst & Consumer Opinions
This section examines recent analyst ratings and consumer feedback related to STERIS plc (STE) for balanced insight.
Stock Grades
Here is a summary of recent verified stock grades from recognized analysts for STERIS plc (STE):
| Grading Company | Action | New Grade | Date |
|---|---|---|---|
| Morgan Stanley | Maintain | Overweight | 2025-08-08 |
| Keybanc | Maintain | Overweight | 2025-07-22 |
| Morgan Stanley | Upgrade | Overweight | 2025-07-15 |
| Morgan Stanley | Maintain | Equal Weight | 2025-05-19 |
| JMP Securities | Maintain | Market Outperform | 2025-05-16 |
| Stephens & Co. | Maintain | Overweight | 2025-05-15 |
| Morgan Stanley | Maintain | Equal Weight | 2025-05-12 |
| JMP Securities | Maintain | Market Outperform | 2025-04-10 |
| Needham | Maintain | Hold | 2025-04-07 |
| JMP Securities | Maintain | Market Outperform | 2025-02-06 |
The overall trend shows a majority of positive ratings with multiple “Overweight” and “Market Outperform” grades, indicating a generally favorable analyst sentiment, while a few hold ratings suggest some caution remains.
Consumer Opinions
Consumers of STERIS plc (ticker: STE) express a mix of appreciation and concerns, reflecting a nuanced view of the company’s products and services.
| Positive Reviews | Negative Reviews |
|---|---|
| High-quality sterilization equipment that improves safety | Customer service response times can be slow |
| Reliable and durable products with consistent performance | Pricing is perceived as higher compared to competitors |
| Strong technical support and knowledgeable staff | Occasional delays in product delivery |
Overall, customers praise STERIS for its reliable and effective sterilization solutions and strong technical support. However, common complaints involve customer service responsiveness and premium pricing, which may require attention to improve satisfaction.
Risk Analysis
Below is a concise assessment table outlining key risk categories relevant to STERIS plc (STE) as of 2026:
| Category | Description | Probability | Impact |
|---|---|---|---|
| Market Valuation | High P/E (36.35) and P/B (3.38) ratios suggest possible overvaluation risk in turbulent markets. | Medium | High |
| Operational Risks | Dependence on healthcare and life sciences sectors with potential regulatory changes. | Medium | Medium |
| Financial Health | Favorable Altman Z-Score (5.92) indicates low bankruptcy risk; moderate ROE (9.31%) is concerning. | Low | Medium |
| Dividend Yield | Low yield (0.98%) may reduce attractiveness to income-focused investors in volatile markets. | High | Low |
| Industry Exposure | Exposure to infection prevention product demand fluctuations amid evolving healthcare trends. | Medium | Medium |
Steris plc shows strong financial health with a safe Altman Z-Score and a very strong Piotroski Score, mitigating bankruptcy risk. However, valuation multiples remain stretched, and ROE underperformance may limit growth potential, warranting caution for risk-sensitive investors.
Should You Buy STERIS plc?
STERIS plc appears to be a moderately profitable company with improving operational efficiency, yet it exhibits a slightly unfavorable moat due to value destruction despite growing returns. Its leverage profile is manageable, supporting a very favorable B rating, suggesting a balanced risk-return profile.
Strength & Efficiency Pillars
STERIS plc exhibits solid financial health marked by an Altman Z-score of 5.92, firmly placing it in the safe zone and signaling low bankruptcy risk. The Piotroski score of 8 underscores very strong financial strength, reflecting robust profitability and operational efficiency. While the return on invested capital (ROIC) at 7.17% slightly trails the weighted average cost of capital (WACC) at 8.2%, indicating the company is currently shedding value, improving ROIC trends suggest growing profitability. Favorable margins, including a net margin of 11.26% and an EBIT margin of 16.16%, complement a conservative debt-to-equity ratio of 0.33, reinforcing financial resilience.
Weaknesses and Drawbacks
The valuation metrics raise caution, with a high price-to-earnings ratio of 36.35 and a price-to-book ratio of 3.38, suggesting a premium valuation that may limit upside potential. Despite strong liquidity indicated by a current ratio of 1.96, the moderate debt-to-equity score flags some leverage concerns. Additionally, the dividend yield is low at 0.98%, which might deter income-focused investors. These factors, combined with a slight deceleration in overall stock momentum and a recent price decline of -1.61%, present near-term market pressure risks that investors should weigh carefully.
Our Verdict about STERIS plc
STERIS plc’s long-term fundamental profile appears favorable, supported by strong financial health and improving profitability. The overall bullish stock trend with increasing volume and buyer dominance over the recent period further supports this outlook. However, the premium valuation and recent deceleration suggest that, despite long-term strength, a cautious wait-and-see approach might be prudent to identify a more attractive entry point. This profile may appear suitable for investors seeking exposure to a financially stable growth company with moderate near-term risks.
Disclaimer: This content is for informational purposes only and does not constitute financial, investment, or other professional advice. Investing in financial markets involves a significant risk of loss, and past performance is not indicative of future results.
Additional Resources
- Universal Beteiligungs und Servicegesellschaft mbH Increases Stake in STERIS plc $STE – MarketBeat (Jan 24, 2026)
- Is it the Right Time to Add STERIS Stock to Your Portfolio? – Yahoo Finance (Jan 09, 2026)
- STERIS plc $STE Stock Position Raised by Locust Wood Capital Advisers LLC – MarketBeat (Jan 22, 2026)
- Veteran healthcare CFO Michael Tokich joins Mettler-Toledo board – Stock Titan (Jan 20, 2026)
- How Investors May Respond To STERIS (STE) Strong Beat On Revenue Growth And Margin Expansion – Sahm (Jan 17, 2026)
For more information about STERIS plc, please visit the official website: steris.com
